(NP (NP (NN Lymphocyte) (NN glucocorticoid) (NN receptor) (NN number)) (PP (IN in) (NP (JJ posttraumatic) (NN stress) (NN disorder))) (. .))
(NP (NP (NN OBJECTIVE)) (: :) (S (NP-SBJ (NP (DT The) (NNS authors) (POS ')) (NN objective)) (VP (VBD was) (S-PRD (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB investigate) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP-SBJ-103 (NN glucocorticoid) (NN receptor) (NNS changes)) (VP (MD may) (VP (VB be) (VP (VBN involved) (NP (-NONE- *-103)) (PP (IN in) (NP (NP (DT the) (NN dysregulation)) (PP (IN of) (NP (DT the) (ADJP (ADJP (JJ hypothalamic-pituitary-adrenal)) (PRN (-LRB- -LRB-) (ADJP (JJ HPA)) (-RRB- -RRB-))) (NN axis))) (PP (IN in) (NP (NP (JJ posttraumatic) (NN stress) (NN disorder)) (PRN (-LRB- -LRB-) (NP (NN PTSD)) (-RRB- -RRB-)))))))))))))))) (. .)))
(NP (NP (NN METHOD)) (: :) (S (NP-SBJ (PRP They)) (VP (VBD measured) (NP (NP-COOD (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN lymphocyte) (JJ cytosolic) (NN glucocorticoid) (NNS receptors)))) (CC and) (NP (NN plasma) (NN cortisol) (NNS concentrations))) (PP-COOD (IN in) (NP (NP (CD 15) (ADJP (RB consecutively) (VBN admitted)) (JJ male) (NN combat) (NN Vietnam) (NNS veterans)) (PP (IN with) (NP (NN PTSD)))) (CC and) (PP (IN in) (NP (NP (DT a) (JJ normal) (NN comparison) (NN group)) (PP (IN of) (NP (CD 11) (NNS subjects)))))))) (. .)))
(NP (NP (NNS RESULTS)) (: :) (S (NP-SBJ-COOD (CC Both) (NP (DT the) (NNS patients)) (CC and) (NP (DT the) (JJ normal) (NN comparison) (NNS subjects))) (VP (VBD showed) (NP (NP (DT a) (JJ morning-to-afternoon) (NN decline)) (PP (IN in) (NP (NN glucocorticoid) (NN receptor) (NNS concentrations))) (, ,) (VP (VBG paralleling) (NP (NP (DT the) (JJ normal) (JJ diurnal) (NN decline)) (PP (IN in) (NP (NN cortisol) (NNS levels))))))) (. .)))
(S (NP-SBJ (NP (DT The) (NN number)) (PP (IN of) (NP (NN glucocorticoid) (NNS receptors)))) (VP (VBD was) (ADJP-PRD (ADJP-COOD (ADJP (ADJP (NP (CD 63) (NN %)) (JJR greater)) (PP (-NONE- *RNR*-46)) (PP (-NONE- *RNR*-47)) (PP-TMP (IN in) (NP (DT the) (NN morning)))) (CC and) (ADJP (ADJP (NP (CD 26) (NN %)) (JJR greater)) (PP (-NONE- *RNR*-46)) (PP (-NONE- *RNR*-47)) (PP-TMP (IN in) (NP (DT the) (NN afternoon))))) (PP-47 (IN in) (NP (NP (DT the) (NNS patients)) (PP (IN with) (NP (NN PTSD))))) (PP-46 (IN than) (FRAG (PP (IN in) (NP (DT the) (JJ normal) (NNS subjects))))))) (. .))
(S-COOD (S (NP-SBJ-48 (NP (DT No) (NN group) (NNS differences)) (PP (IN in) (NP (NN cortisol) (NNS levels)))) (VP (VBD were) (VP (VBN observed) (NP (-NONE- *-48))))) (, ,) (CC nor) (SINV (VBD were) (NP-SBJ-COOD (NP (NN glucocorticoid) (NN receptor) (NN number)) (CC and) (NP (NN cortisol) (NNS levels))) (ADJP-PRD (VBD correlated))) (. .))
(S (NP-SBJ (NP (DT The) (NN number)) (PP (IN of) (NP (NN morning) (NN glucocorticoid) (NNS receptors)))) (VP (VBD was) (ADJP-PRD (RB positively) (VBN correlated) (PP (IN with) (NP (NP (NNS symptoms)) (PP (IN of) (NP-COOD (NP (NN PTSD)) (CC and) (NP (NN anxiety)))))))) (. .))
(NP (NP (NNS CONCLUSIONS)) (: :) (S (NP-SBJ (DT These) (NNS results)) (VP (VBP provide) (NP (NP (JJ further) (NN evidence)) (PP (IN for) (NP (NP (DT a) (NN dysregulation)) (PP (IN of) (NP (DT the) (JJ HPA) (NN axis))) (PP (IN in) (NP (NN PTSD))))))) (. .)))
(S (NP-SBJ (DT The) (NN finding) (SBAR (IN that) (S (NP-SBJ (NP (NNS patients)) (PP (IN with) (NP (NN PTSD)))) (VP (VBD had) (NP (NP (NP (DT a) (ADJP (RB substantially) (JJR greater)) (NN number)) (PP (IN of) (NP (NN lymphocyte) (NN glucocorticoid) (NNS receptors)))) (PP (IN than) (NP (JJ normal) (NN comparison) (NNS subjects)))))))) (VP (VBZ is) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (NP (NP (DT the) (NNS authors) (POS ')) (JJ previous) (NNS observations)) (PP (IN of) (NP (NP (JJ low) (JJ 24-hour) (JJ urinary) (NN cortisol) (NN excretion)) (PP (IN in) (NP (NP (NNS subjects)) (PP (IN with) (NP (NN PTSD))))))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NP (DT the) (NN receptor) (NNS changes)) (VP (VBN observed) (NP (-NONE- *)))) (VP (VBP are) (ADJP-PRD (JJ opposite) (PP (IN of) (NP (NP (DT those)) (VP (VBN reported) (NP (-NONE- *)) (PP (IN in) (NP (JJ major) (JJ depressive) (NN disorder)))))))) (. .))
(S (NP-SBJ (DT The) (JJ present) (NNS data)) (, ,) (PP (IN along) (IN with) (NP (NP (JJ other) (NNS findings)) (PP (IN of) (NP (NP (JJ HPA) (NNS abnormalities)) (PP (IN in) (NP (NN PTSD))))))) (, ,) (VP (VBP support) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (DT a) (JJR greater) (JJ negative) (NN feedback) (NN sensitivity)) (PP (IN at) (NP (NP (QP (CD one) (CC or) (JJR more)) (NNS levels)) (PP (IN of) (NP (DT the) (JJ HPA) (NN axis))))))))) (. .))
